Letter from the editor.
Reichert
Janice M
JM
D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology / Q000378:metabolism / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001168:Arthritis / Q000188:drug therapy; D001327:Autoimmune Diseases / Q000188:drug therapy; D001709:Biotechnology / Q000379:methods*; D017277:Drug Approval; D004353:Drug Evaluation, Preclinical / Q000379:methods; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C506968:motavizumab; C529000:golimumab; C502936:tocilizumab